Substance / Medication

Dostarlimab

SNOMED 1156877005 UMLS C5242455

Overview

Active Ingredient

dostarlimab

RxNorm CUI

2539967

Labeler: GlaxoSmithKline LLCUpdated: 2025-09-02T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Endometrial carcinoma

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Efficacy of dostarlimab in recurrent or advanced mismatch Repair-Deficient endometrial Cancer as a Single-Agent therapy: A systematic review and Meta-Analysis.

Rezaei Ramazan, Khani Hedieh Haji Khodaverdi · Daru · 2025

PMID: 40616648Meta-AnalysisFull text (PMC)

Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.

Valabrega Giorgio, Powell Matthew A, Hietanen Sakari et al. · Int J Gynecol Cancer · 2025

PMID: 39322611RCT

Dostarlimab and niraparib in primary advanced ovarian cancer.

Hardy-Bessard A-C, Pujade-Lauraine E, Moore R G et al. · Ann Oncol · 2025

PMID: 40461381RCT

Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel.

Chase Dana M, Herrstedt Jørn, Miller Eirwen M et al. · Int J Gynecol Cancer · 2025

PMID: 40616865RCT

Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).

Powell Matthew A, Cibula David, O'Malley David M et al. · Gynecol Oncol · 2025

PMID: 39531903RCT

Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.

Reck Martin, Granados Ana Laura Ortega, de Marinis Filippo et al. · Eur J Cancer · 2024

PMID: 39378565RCT

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.

Powell M A, Bjørge L, Willmott L et al. · Ann Oncol · 2024

PMID: 38866180RCT

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.

Mirza Mansoor R, Chase Dana M, Slomovitz Brian M et al. · N Engl J Med · 2023

PMID: 36972026RCT

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.

André Thierry, Berton Dominique, Curigliano Giuseppe et al. · JAMA Netw Open · 2023

PMID: 37917058RCTFull text (PMC)

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial.

Lim Sun Min, Peters Solange, Ortega Granados Ana Laura et al. · Nat Commun · 2023

PMID: 37951954RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Dostarlimab (substance)
SNOMED CT: 1156877005
UMLS CUI: C5242455
RxNorm CUI: 2539967
Labeler: GlaxoSmithKline LLC

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.